fin1 Antibody

What is FN1 and why is it an important research target?

Fibronectin 1 (FN1) is a high-molecular-weight glycoprotein (~263 kDa calculated, often observed at ~285 kDa in gel electrophoresis) that exists in two primary forms: a soluble dimeric form secreted by hepatocytes into plasma (plasma FN) and a cellular form produced by fibroblasts, epithelial cells, and other cell types that is deposited as fibrils in the extracellular matrix . FN1 plays crucial roles in cell adhesion, migration, wound healing, blood coagulation, host defense mechanisms, and metastasis, making it a significant target in various research areas including developmental biology, cancer research, cardiovascular studies, and signal transduction investigations . The FN1 gene contains three regions subject to alternative splicing, potentially generating up to 20 different transcript variants, which adds complexity to its study and functional characterization .

What are the key applications for FN1 antibodies in experimental research?

FN1 antibodies are instrumental in multiple experimental applications, primarily Western Blotting (WB), Immunohistochemistry (IHC), and Immunofluorescence (IF) . According to available research data, FN1 antibodies have been verified for use in specific samples including HeLa cells for Western blotting, rat liver tissues for immunohistochemistry, and human appendix tissues for immunofluorescence studies . These antibodies enable researchers to visualize FN1 distribution in tissues, quantify expression levels, and characterize its involvement in physiological and pathological processes. The diversity of applications reflects FN1's multifunctional nature in biological systems and its varied expression patterns across different tissues and cellular compartments.

How do different FN1 transcript variants impact antibody selection?

FN1 transcript variants significantly influence antibody selection strategies due to the complex alternative splicing pattern of the FN1 gene. RNA-seq data reveals multiple protein-coding transcripts with varying inclusion of key domains:

When selecting antibodies, researchers must consider which specific domains or isoforms they aim to detect . For comprehensive detection of all FN1 variants, antibodies targeting conserved regions are preferred, while studies focusing on specific splice variants require antibodies that recognize unique epitopes within the EDA, EDB, or V regions.

What are the optimal dilution ratios for FN1 antibodies across different applications?

Determining optimal dilution ratios for FN1 antibodies is critical for experimental success. Based on validated protocols, the following ranges are recommended for monoclonal FN1 antibodies:

• Western Blotting (WB): 1:500-1:2000 dilution

• Immunohistochemistry (IHC): 1:50-1:300 dilution

• Immunofluorescence (IF): 1:100-1:300 dilution

These ranges provide starting points, but researchers should perform optimization experiments for their specific antibody lot and sample type. Titration experiments are essential to determine the optimal signal-to-noise ratio for each application. For Western blotting, a dilution series should be tested against control samples with known FN1 expression. For IHC and IF applications, positive control tissues (such as rat liver or human appendix) should be used to establish optimal dilution parameters . The optimization process should account for variables such as tissue fixation methods, antigen retrieval protocols, and detection systems used.

How should researchers address the molecular weight discrepancy in FN1 detection?

FN1 antibodies frequently detect bands at molecular weights different from the calculated 263 kDa, with an observed molecular weight often around 285 kDa . This discrepancy is a common challenge in FN1 research and can be attributed to several factors:

• Post-translational modifications: FN1 undergoes extensive glycosylation and other modifications that increase its apparent molecular weight.

• Alternative splicing: The various FN1 isoforms have different molecular weights based on included/excluded exons.

• Sample preparation conditions: Denaturation conditions, reducing agents, and buffer compositions can affect protein migration patterns.

To address this discrepancy, researchers should:

• Include appropriate positive controls with known FN1 expression

• Use molecular weight markers that extend to high molecular weights (>250 kDa)

• Document the actual observed molecular weight in their specific experimental system

• Consider performing parallel detection methods (e.g., mass spectrometry) to confirm identity

• Recognize that the observed band size inconsistency is normal for FN1 and does not necessarily indicate poor antibody specificity

What validation steps are essential before using a new FN1 antibody lot?

Before implementing a new FN1 antibody lot in research protocols, several validation steps should be performed:

• Positive control testing: The antibody should be tested against tissues or cell lines with established FN1 expression. Verified samples include HeLa cells for WB, rat liver for IHC, and human appendix for IF applications .

• Specificity assessment: Perform Western blotting with recombinant FN1 protein or cell lysates with known FN1 expression levels. The antibody should detect bands at the expected molecular weight range (~263-285 kDa).

• Cross-reactivity evaluation: Test the antibody against samples from different species if cross-species reactivity is claimed. The FN1 monoclonal antibody referenced in the search results claims reactivity with human, mouse, and rat samples .

• Application-specific validation: For each intended application (WB, IHC, IF), perform method-specific validations:

  • For WB: Verify band specificity, optimal dilution, and blocking conditions

  • For IHC: Establish antigen retrieval method, optimal dilution, and counterstaining protocol

  • For IF: Determine fixation method, permeabilization protocol, and appropriate controls

• Reproducibility testing: Perform replicate experiments to ensure consistent results across multiple tests.

How can FN1 antibodies be utilized to study alternative splicing patterns?

FN1 undergoes complex alternative splicing that generates multiple isoforms with distinct functional properties. Researchers can leverage FN1 antibodies to investigate these splicing patterns through:

• Isoform-specific antibodies: Using antibodies that specifically recognize the EDA, EDB, or V regions to differentiate between splice variants . This approach requires careful antibody selection or custom antibody development targeting unique epitopes within alternatively spliced regions.

• Comparative profiling: Implementing a panel of different FN1 antibodies targeting distinct domains to create expression profiles of different tissues or disease states.

• Immunoprecipitation followed by mass spectrometry: Using FN1 antibodies to pull down FN1 proteins, followed by mass spectrometry to identify specific isoforms present in a sample.

• Correlation with transcriptomic data: Combining antibody-based protein detection with RNA-seq data, as illustrated in the research data showing differential expression of FN1 transcripts . The table provided in search result demonstrates how RNA-seq can quantify the expression levels of different FN1 transcripts, with base mean values ranging from 3,472.7 to 430,585.6 for protein-coding variants.

This multimodal approach allows researchers to correlate protein expression patterns with transcript abundance, providing insights into post-transcriptional regulation mechanisms affecting FN1 isoform expression.

What considerations are important when using FN1 antibodies in disease model research?

When employing FN1 antibodies in disease model investigations, researchers should consider:

• Disease-specific isoform expression: Different pathological conditions may alter the splicing pattern of FN1. For instance, the EDB domain is prominently expressed during embryogenesis and in certain tumor tissues but is largely absent in normal adult tissues, making EDB-specific antibodies valuable for cancer research .

• Microenvironment factors: The extracellular matrix composition varies significantly across disease states and can affect FN1 conformation and epitope accessibility. Researchers should optimize antibody conditions specifically for each disease model.

• Post-translational modifications: Disease states can alter FN1 glycosylation patterns and other modifications, potentially affecting antibody recognition. Researchers should verify antibody performance in their specific disease model.

• Comparative analysis: Always include appropriate controls, such as matched normal tissues or non-diseased models, to establish baseline FN1 expression and distribution patterns.

• Temporal dynamics: Consider time-course studies to capture dynamic changes in FN1 expression and localization during disease progression, particularly in models where extracellular matrix remodeling is a key feature.

How do emerging antibody technologies impact FN1 research approaches?

Recent advances in antibody technology are transforming FN1 research capabilities:

• AI-driven antibody design: As highlighted in the Baker Lab's research, artificial intelligence tools like RFdiffusion are being developed to design novel antibodies with precise binding characteristics . This technology creates new opportunities for developing highly specific antibodies targeting distinct FN1 domains or conformational epitopes.

• Single-chain variable fragments (scFvs): The development of human-like antibodies and antibody fragments, such as scFvs, offers new possibilities for both research and therapeutic applications . These smaller antibody formats may provide better tissue penetration and epitope access in complex extracellular matrix environments where FN1 is abundant.

• Multiplex imaging technologies: Advanced techniques like multiplex immunofluorescence and imaging mass cytometry allow simultaneous detection of FN1 along with multiple other proteins, enabling comprehensive analysis of FN1's interactions with other extracellular matrix components and cellular receptors.

• Antibody engineering: Site-specific conjugation technologies enable precise labeling of antibodies without compromising binding properties, improving signal-to-noise ratios in imaging and quantification applications.

How should researchers troubleshoot non-specific binding with FN1 antibodies?

Non-specific binding is a common challenge when working with FN1 antibodies due to FN1's abundance in serum and its structural complexity. To address this issue:

• Optimize blocking conditions: Test different blocking agents (BSA, non-fat dry milk, normal serum) at various concentrations and incubation times. The high abundance of FN1 in serum necessitates careful selection of blocking reagents to prevent background issues.

• Adjust antibody dilution: Non-specific binding often occurs when antibody concentration is too high. Perform a dilution series to identify the optimal concentration that provides specific signal with minimal background.

• Modify washing protocols: Implement more stringent washing steps by increasing the number of washes, wash duration, or detergent concentration in wash buffers. This is particularly important for FN1 due to its sticky nature and tendency to adhere to various surfaces.

• Pre-absorb antibodies: For tissues with high endogenous FN1, consider pre-absorbing the antibody with the sample matrix to reduce non-specific interactions.

• Include appropriate controls: Always run negative controls (omitting primary antibody) and isotype controls (using non-specific IgG of the same isotype) to distinguish between specific and non-specific signals.

What are effective strategies for studying FN1 in tissues with high endogenous expression?

Researching FN1 in tissues with abundant endogenous expression presents unique challenges:

• Implement antigen retrieval optimization: Different tissues may require specific antigen retrieval methods to expose FN1 epitopes effectively. Compare heat-induced epitope retrieval methods (citrate, EDTA, Tris buffers) and enzymatic methods to determine the most effective approach for your specific tissue.

• Utilize tyramide signal amplification: For tissues with low signal-to-noise ratios, tyramide signal amplification can enhance specific signals while maintaining low background levels.

• Consider thick-section confocal microscopy: For complex three-dimensional structures rich in FN1, thick-section imaging with confocal microscopy provides better spatial resolution of FN1 organization in the extracellular matrix.

• Employ quantitative image analysis: Implement automated image analysis tools to quantify FN1 expression levels, reducing subjective interpretation and enabling detection of subtle changes in expression or localization patterns.

• Use complementary approaches: Complement antibody-based detection with other methodologies such as in situ hybridization to detect FN1 transcripts or functional assays to assess FN1 activity rather than just abundance.

How can FN1 antibodies contribute to research on influenza immunity?

Recent research has explored the relationship between antibody effector functions and influenza immunity, highlighting potential applications for antibody research methodologies:

The study of influenza-specific antibody breadth and function has revealed important insights into immune correlates of protection against pandemic influenza strains. Research indicates that antibody effector functions, including antibody-dependent cellular cytotoxicity (ADCC), play critical roles in protective immunity . While this research specifically focuses on influenza antibodies rather than FN1 antibodies, the methodological approaches demonstrate how antibody studies can reveal important insights into disease mechanisms.

Similar methodological approaches could be applied to investigate potential roles of FN1 and anti-FN1 immune responses in respiratory infections, potentially revealing:

• Changes in FN1 expression patterns during infection

• Roles of FN1 in viral attachment or immune cell recruitment

• Potential involvement of FN1 in tissue repair following infection-induced damage

What considerations are important when designing experiments to study FN1 interaction with other extracellular matrix components?

When investigating FN1 interactions with other matrix components:

• Select appropriate co-immunoprecipitation conditions: The large size and complex structure of FN1 require careful optimization of buffer conditions for co-immunoprecipitation experiments to maintain protein-protein interactions while minimizing non-specific binding.

• Implement proximity ligation assays: This technique can detect protein-protein interactions in situ with high sensitivity and specificity, making it valuable for studying FN1 interactions within the native tissue architecture.

• Consider fixation impact: Different fixation methods can significantly affect the preservation of protein-protein interactions in the extracellular matrix. Compare multiple fixation protocols to determine optimal conditions for preserving FN1 interactions.

• Utilize recombinant domain-specific constructs: Express specific domains of FN1 to investigate their individual interactions with other extracellular matrix components, providing insights into domain-specific functions.

• Implement advanced imaging techniques: Super-resolution microscopy and electron microscopy provide nanoscale resolution for visualizing FN1 fibril organization and its spatial relationships with other extracellular matrix components.